News Coverage
- 2021
-
October 13, 2021 October 4, 2021 Clinical Catch-Up: September 27-October 1
Learn MoreSeptember 27, 2021 Devimistat Now Being Explored for the Treatment of Clear Cell Sarcomas in the United States
Learn MoreSeptember 27, 2021 Rafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613® (devimistat) in Combination with Hydroxychloroquine in Patients with Relapsed Clear Cell Sarcoma Begins Enrollment at City of Hope in Duarte, Calif.
Learn MoreSeptember 3, 2021 Devimistat Plus Gemcitabine/Cisplatin Moves to Phase 2 Setting in Frontline Biliary Tract Cancer
Learn MoreAugust 30, 2021 Targeted Oncology: Devimistat With Gemcitabine and Cisplatin Advances to Phase 2 in Biliary Tract Cancer
Learn MoreAugust 30, 2021 BioSpace: Clinical Catch-Up: August 23-27
Learn MoreAugust 19, 2021 Outcomes Rocket: Sanjeev Luther, President & CEO of Rafael Pharmaceuticals: Discovering Therapy Options for Hard-to-Treat and Rare Cancers
Learn MoreJuly 7, 2021 OncLive: Novel Combination May Break Outcomes Stalemate in Pancreatic Cancer
Learn MoreJuly 6, 2021 BioSpace: Clinical Catch-Up: June 28-July 2
Learn MoreJuly 6, 2021 OncLive: Phase 3 ARMADA 2000 Trial of Devimistat in Relapsed/Refractory AML to Continue
Learn MoreJuly 1, 2021 Cancer Network: Devimistat Demonstrates Positive Outcomes in Relapsed/Refractory Acute AML
Learn MoreJuly 1, 2021 Life Science Leader: Against All Odds: Advancing From R&D To Phase 3
Learn MoreJuly 1, 2021 Outsourcing-Pharma: Experts to talk rare and orphan diseases, patient experience at webinar
Learn MoreApril 15, 2021 OncLive: Novel Agents Move the Needle Forward in Metastatic Pancreatic Cancer
Learn MoreApril 5, 2021 BioSpace: Clinical Catch-Up: March 29-April 2
Learn MoreApril 2, 2021 Targeted Oncology: Enrollment Milestone Reached for Phase 3 Study of Devimistat in AML
Learn MoreMarch 22, 2021 Applied Clinical Trials: Cancer Won’t Wait for COVID to End: Conducting Trials Amid the Coronavirus Pandemic
Learn MoreMarch 18, 2021 Healthline: Why Are So Few Black People Included in Cancer Drug Trials?
Learn MoreMarch 17, 2021 BioSpace: Get to Know Sanjeev Luther, CEO and Board Member of Rafael Pharmaceuticals
Learn MoreMarch 15, 2021 OncLive: Investigators Focus Devimistat Study on Older Patients With AML
Learn MoreJanuary 25, 2021 Healio: FDA grants priority review, fast track status to several hematology/oncology products
Learn More - 2020
-
December 31, 2020 Healio: Top in hem/onc: Cancer care amid COVID-19, tumor bed boost
Learn MoreDecember 23, 2020 Healio: 10 FDA actions that may impact your practice
Learn MoreDecember 21, 2020 Healio: FDA grants fast track designation to CPI-613 for AML
Learn MoreDecember 17, 2020 Oncology Nursing News: Devimistat Granted Fast Track Designation for AML Treatment
Learn MoreDecember 16, 2020 Pharmacy Times: Devimistat Gets FDA Fast Track Designation for Acute Myeloid Leukemia
Learn MoreDecember 15, 2020 BioWorld: Regulatory actions for Dec. 15, 2020
Learn MoreDecember 15, 2020 OncLive: FDA Grants Fast Track Designation to Devimistat for AML
Learn MoreDecember 15, 2020 Targeted Oncology: FDA Grants Fast Track Designation to Devimistat in Acute Myeloid Leukemia
Learn MoreDecember 10, 2020 Outsourcing-Pharma: FDA Grants Orphan Status to Rafael Cancer Drug
Learn MoreDecember 7, 2020 BioSpace: Clinical Catch-Up: November 30-December 4
Learn MoreDecember 2, 2020 Targeted Oncology: A Look Back at the FDA News from November 2020
Learn MoreNovember 25, 2020 Oncology Nursing News: Devimistat Granted Orphan Drug Status for Soft Tissue Sarcoma
Learn MoreNovember 24, 2020 OncLive: Devimistat Granted Orphan Drug Status for Soft Tissue Sarcoma
Learn MoreNovember 21, 2020 Healio: Eight important updates for Pancreatic Cancer Awareness Month
Learn MoreNovember 16, 2020 Healio: FDA Grants Fast Track Designation to CPI-613 for Pancreatic Cancer
Learn MoreNovember 13, 2020 Targeted Oncology: Trending News on Targeted Oncology, Week of November 13, 2020
Learn MoreOctober 29, 2020 Targeted Oncology: FDA Grants Orphan Drug Designation to Devimistat for Soft Tissue Sarcoma
Learn MoreOctober 15, 2020 Authority Magazine: Meet The Disruptors: Sanjeev Luther of Rafael Pharmaceuticals On The Three Things You Need To Shake Up Your Industry
Learn MoreOctober 15, 2020 Pharmaceutical Executive: Episode 67: Succeeding Through Adversity
Learn MoreOctober 12, 2020 BioWorld: The new dealmaking normal, will it continue post-pandemic?
Learn MoreAugust 24, 2020 Targeted Oncology: Promising Phase 3 Study of CPI-613 in Metastatic Pancreatic Cancer Achieves Target Enrollment Early
Learn MoreJuly 27, 2020 ROI-NJ: Some Local Firms Hope to Bring Bigger Portion of Pharma Manufacturing Back to U.S. — and N.J.
Learn MoreJune 22, 2020 OncLive: Dr. Alistar on the Need to Develop Biomarkers in Pancreatic Cancer
Learn MoreJune 9, 2020 OncLive: Philip Highlights Promise of Devimistat in Pancreatic Cancer
Learn MoreMay 25, 2020 The Jerusalem Post: Despite COVID-19, Pivotal Pancreatic Cancer Study in Israel Hits Benchmark
Learn MoreApril 30, 2020 RARECast: Targeting the Metabolism of Rare Cancers
Learn MoreApril 28, 2020 Clinical Leader: COVID-19 Presents Unique Challenges For Oncology Trials
Learn MoreApril 8, 2020 Empowered Patient Podcast: Developing Cancer Metabolism Drugs with Sanjeev Luther Rafael Pharmaceuticals
Learn MoreMarch 9, 2020 National Center for Biotechnology Information: The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
Learn MoreMarch 7, 2020 OncLive: Dr. Mettu on the Potential of CPI-613 in Metastatic Pancreatic Cancer
Learn More - 2019
-
December 3, 2019 Targeted Oncology: Phase II Devimstat Study Expanded to Increase Access for Patients With Burkitts Lymphoma/Leukemia
Learn MoreNovember 10, 2019 Huffington Post: 13 Unexpected Reasons Why You Might Have A Fever
Learn MoreOctober 31, 2019 Clinical Leader: Rafael Pharmaceuticals Is Starving Cancer Cells
Learn MoreOctober 9, 2019 Targeted Oncology: New Phase III Trial Evaluates Devimistat Plus FOLFIRNOX in Metastatic Pancreatic Cancer
Learn MoreSeptember 5, 2019 Authority Magazine: 5 Things I Wish Someone Told Me Before I Became the CEO of Rafael Pharmaceuticals, With Sanjeev Luther
Learn MoreSeptember 4, 2019 MSN: 30 Things Oncologists Do to Prevent Cancer
Learn MoreAugust 1, 2019 Life Science Leader: Strategies For Success: Developing Drugs For Orphan Diseases
Learn MoreJuly 18, 2019 The Jerusalem Post: Breakthrough Pancreatic Cancer Treatment Phase III Trial opens in Israel
Learn MoreJuly 11, 2019 OncLive: Devimistat Could Have Practice-Changing Potential in Burkitt Lymphoma
Learn MoreJune 11, 2019 DDN News: Special Report on Cancer: Metabolic renaissance?
Learn MoreMay 29, 2019 U.S. News & World Report: Alex Trebek Says His Pancreatic Cancer Is ‘Near Remission’
Learn MoreMay 13, 2019 Winston Salem Journal: Dr. Zanetta Lamar: Cancer metabolism: Gaining momentum in the fight to stop cancer
Learn MoreMarch 29, 2019 Scientific American: A New Way to Fight Cancer
Learn MoreMarch 18, 2019 Investing News Network: Rafael Pharma Stands Out with Drugs Treating Difficult Cancers
Learn MoreMarch 12, 2019 CRAIN’S New York Business: NJ firm advancing drug for pancreatic, hard-to-treat cancers
Learn MoreMarch 7, 2019 OncLive: Dr. Mettu on the Potential of CPI-613® in Metastatic Pancreatic Cancer
Learn More - 2017
-
June 13, 2017 Drug Discovery News: Special Report on Cancer Metabolomics- Into the metabolic maelstrom
Learn MoreMarch 27, 2017 BioWorld: Next-generation oncology: New technologies and MOAs
Learn MoreMarch 24, 2017 BIOCENTURY: How Cornerstone’s CPI-613® leapfrogged to pivotal trials in AML and pancreatic cancer
Learn MoreMarch 23, 2017 MedCity News: Cornerstone gets green light for two pivotal cancer trials
Learn MoreMarch 17, 2017 PM 360 Movers and Shakers: Chi Van Dang, M.D., Ph.D., appointed to Cornerstone’s Board of Directors. Will also serve as Chair of its Scientific and Medical Advisory Boards
Learn MoreFebruary 14, 2017 WCTC-AM: Interview with Sanjeev Luther (COO, Cornerstone Pharmaceuticals)
Learn MoreFebruary 8, 2017 FirstWorld Pharma: Cornerstone Pharmaceuticals Announces the Addition of World-Renowned Experts to Scientific and Medical Advisory Boards
Learn MoreJanuary 30, 2017 BioWorld Appointments and Advancements:- Cornerstone’s new Board of Directors (Subscription Required)
Learn MoreJanuary 16, 2017 The Price of Business Radio: JP Morgan Biotech, Sanjeev Luther (COO, Cornerstone Pharmaceuticals) and Tim Pardee (Chief Oncologist, Cornerstone Pharmaceuticals) on CPI-613®
Learn MoreJanuary 14, 2017 Vital Options International: Dr Zanetta Lamar at ASH 2016- The data collected by Wake Forest Baptist Health
Learn MoreJanuary 14, 2017 Vital Options International: Dr Zanetta Lamar at ASH 2016- The cost of therapy and quality of care
Learn MoreJanuary 14, 2017 Vital Options International: Dr Timothy Pardee at ASH 2016- New Therapeutic Methods
Learn MoreJanuary 14, 2017 Vital Options International: Dr Timothy Pardee at ASH 2016- Addressing patients participating in clinical trials
Learn More - 2016
-
December 5, 2016 ecancer: Dr Timothy Pardee at ASH 2016 on TCA cycle inhibition by CPI-613® in older AML patients
Learn MoreDecember 5, 2016 ecancer: Dr Zanetta Lamar at ASH 2016 on dose escalation of CPI-613® with bendamustine for relapsed T Cell NHL
Learn More - 2015
-
January 9, 2015 OncLive: Dr. Powell at ASH 2014 on CPI-613®, Cytarabine, Mitoxantrone Combo for AML
Learn More - 2014
-
September 11, 2014 OncLive: Dr. Pardee on CPI-613®for Patients With R/R AML
Learn More - 2013
-
December 20, 2013 OncLive: Dr. Pardee Provides an Update on CPI-613® in advanced hematologic malignancies
Learn MoreNovember 1, 2013 Pharmaceutical Business Review: Cornerstone initiates Phase II trial of CPI-613® to treat metastatic pancreatic cancer patients
Learn MoreNovember 1, 2013 Drug Development Technology: Cornerstone begins Phase II study of pancreatic cancer drug
Learn MoreNovember 1, 2013 BioWorld Today: Clinic Roundup (subscription required)
Learn MoreOctober 28, 2013 Drug Development Technology: Cornerstone begins Phase II trial of lung cancer drug
Learn MoreOctober 17, 2013 BioPharma International: Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation
Learn MoreOctober 11, 2013 LymphomaInfo.net: Cornerstone Gets Orphan Drug Status For MDS Treatment
Learn MoreOctober 7, 2013 Medical News Today: Cornerstone Pharmaceuticals receives FDA orphan drug designation of CPI-613® for treatment of myelodysplastic syndrome
Learn MoreOctober 4, 2013 Hematology Times: Drug gets orphan designation for MDS (Registration Required)
Learn MoreOctober 3, 2013 Oncology Times: FDA Grants MDS Drug CPI-613® Orphan Drug Status
Learn MoreOctober 3, 2013 The MDS Beacon: Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation Of CPI-613® For Treatment Of Myelodysplastic Syndrome
Learn MoreJuly 25, 2013 OncLive: Dr. Powell Discusses the Next Steps for CPI-613®
Learn MoreJuly 10, 2013 OncLive: Dr. Pardee on CPI-613® in Hematologic Malignancies
Learn MoreJune 11, 2013 OncLive: Dr. Powell Discusses CPI-613® in Hematologic Malignancies
Learn More - 2011
-
December 14, 2011 Drug Discovery & Development: Cornerstone Releasing CPI-613® Data
Learn MoreDecember 13, 2011 BioWorld Today: ASH Roundup (subscription required)
Learn MoreDecember 6, 2011 Drug Discovery & Development: On Target Delivery
Learn MoreAugust 15, 2011 BioCentury: Powering down cancer
Learn MoreAugust 1, 2011 BioWorld Today: Bench Press (subscription required)
Learn More - 2010
-
November 29, 2010 The New York Times: Fuel lines of tumors are new target
Learn MoreSeptember 1, 2010 Start-Up Magazine: Profile on Cornerstone Pharmaceuticals
Learn MoreAugust 1, 2010 Drug Discovery News: Trends in cancer research
Learn MoreMay 1, 2010 Drug Discovery News: Cancer research turns a corner
Learn More